Gensight Biologics SA (SIGHT) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.20x
Gensight Biologics SA (SIGHT) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of €-6.49 Million could theoretically repay 0% of its total liabilities (€33.20 Million) in one year. See SIGHT financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.20x
Operating CF / Total Liabilities
Operating Cash Flow
€-6.49 Million
EUR
Total Liabilities
€33.20 Million
EUR
Data as of
Dec 2025
Most recent filing
Gensight Biologics SA Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Gensight Biologics SA across 13 annual periods. For the full cash flow conversion analysis, see Gensight Biologics SA cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Gensight Biologics SA (2013–2025)
Year-by-year debt coverage analysis for Gensight Biologics SA.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | €-9.38 Million | €33.20 Million | ▲ +17.7% |
| 2024 | -0.34x | €-12.94 Million | €37.68 Million | ▲ +44.5% |
| 2023 | -0.62x | €-24.66 Million | €39.83 Million | ▲ +24.4% |
| 2022 | -0.82x | €-33.75 Million | €41.22 Million | ▼ -94.3% |
| 2021 | -0.42x | €-17.14 Million | €40.66 Million | ▼ 0.0% |
| 2020 | -0.42x | €-15.04 Million | €35.69 Million | ▲ +68.9% |
| 2019 | -1.36x | €-28.11 Million | €20.74 Million | ▲ +37.4% |
| 2018 | -2.17x | €-28.38 Million | €13.11 Million | ▲ +16.8% |
| 2017 | -2.60x | €-18.78 Million | €7.22 Million | ▲ +21.9% |
| 2016 | -3.33x | €-19.64 Million | €5.89 Million | ▼ -92.6% |
| 2015 | -1.73x | €-12.09 Million | €6.98 Million | ▼ -33.0% |
| 2014 | -1.30x | €-5.52 Million | €4.24 Million | ▼ -27.2% |
| 2013 | -1.02x | €-1.95 Million | €1.91 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.